Living with severe hemophilia A means constantly managing the risk of dangerous bleeds, often with frequent, lifelong infusions of clotting factor. A new review of the evidence asks if gene therapy could change that daily reality. The analysis found that, compared to standard factor VIII prophylaxis, gene therapy was linked to a reduction in annual bleeding rates. In the first year, it also boosted the body's own factor VIII activity, though that level tended to decline over time. Most strikingly, the use of factor VIII infusions dropped by more than 96% by the fourth year after gene therapy, and between 0% and 33% of people returned to needing regular prophylaxis.
The people in these studies were adults with severe or moderately severe hemophilia A. While the treatment was generally manageable, side effects were common. Most were mild to moderate, with temporary rises in liver enzymes being a typical issue that doctors managed with steroid medications.
It's important to view these promising findings with clear eyes. The review itself notes a moderate risk of bias in the included studies. The big, unanswered questions are about durability and long-term safety. We don't yet know how long the increased factor VIII activity from a single gene therapy treatment will last, or what the safety profile looks like over many years. This analysis shows a potentially transformative benefit in reducing treatment burden, but it's a picture that's still developing.